AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Dimethyladenosine transferase 1, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8WVM0

UPID:

TFB1M_HUMAN

Alternative names:

Mitochondrial 12S rRNA dimethylase 1; Mitochondrial transcription factor B1; S-adenosylmethionine-6-N', N'-adenosyl(rRNA) dimethyltransferase 1

Alternative UPACC:

Q8WVM0; Q05DR0; Q9Y384

Background:

Dimethyladenosine transferase 1, mitochondrial, also known as mitochondrial 12S rRNA dimethylase 1, plays a crucial role in mitochondrial function. It is a S-adenosyl-L-methionine-dependent methyltransferase, specifically targeting mitochondrial 12S rRNA. This enzyme is vital for the basal transcription of mitochondrial DNA, interacting with POLRMT and TFAM to stimulate transcription beyond its methyltransferase activity.

Therapeutic significance:

Understanding the role of Dimethyladenosine transferase 1, mitochondrial could open doors to potential therapeutic strategies. Its critical function in mitochondrial DNA transcription and rRNA modification underscores its potential as a target for therapeutic intervention in diseases linked to mitochondrial dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.